WO1997013522A1 - Production de peptides d : methodes et compositions - Google Patents

Production de peptides d : methodes et compositions Download PDF

Info

Publication number
WO1997013522A1
WO1997013522A1 PCT/US1996/016358 US9616358W WO9713522A1 WO 1997013522 A1 WO1997013522 A1 WO 1997013522A1 US 9616358 W US9616358 W US 9616358W WO 9713522 A1 WO9713522 A1 WO 9713522A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
ligand
amino acid
antibody
receptor
Prior art date
Application number
PCT/US1996/016358
Other languages
English (en)
Inventor
Barry Robson
Original Assignee
Gryphon Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gryphon Sciences filed Critical Gryphon Sciences
Priority to JP9515247A priority Critical patent/JP2000500431A/ja
Priority to AU74422/96A priority patent/AU7442296A/en
Priority to EP96936413A priority patent/EP0862447A1/fr
Publication of WO1997013522A1 publication Critical patent/WO1997013522A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • achiral essential amino acid is glycine.
  • D and L are used to refer to the configuration of the molecule around its chiral center.
  • the chiral center of an amino acid is the alpha carbon, and whether an amino acid is of the D configuration or the L configuration depends upon the stereoisomeric conventions established by Emil Fisher.
  • a chiral amino acid can exist as stereoisomers, which are identical chemical structures that are mirror images of each other. Both stereoisomers are often referred to as an enantiomeric pair, and a stereoisomer is often referred to as an enantiomer, which is a nonsuperimposable mirror image of the other stereoisomer/enantiomer.
  • L-amino acids All of the naturally occurring chiral amino acids exist in the L configuration, and are referred to generally as L-amino acids.
  • the stereoisomer of each chiral amino acid in the L-configuration is referred to as a D-amino acid.
  • a D-amino acid is one which has a configuration corresponding to the D- stereoisomer of the two stereoisomers of glyceraldehyde, L-glyceraldehyde and D- glyceraldehyde.
  • D-amino acid, D-polypeptide or D-peptide stereoisomers that have the same stereo chemical configuration as D-glyceraldehyde are designated as D-, and those having the same configuration as L-glyceraldehyde are designated as D-, and those having the same configuration as L-glyceraldehyde are designated as D-, and those having the same configuration as L-glyceraldehyde are designated as D-, and those having the same configuration as L-glyceraldehyde are designated as
  • D-amino acids also occur naturally in proteins in man as the result of post- translational modification by racemases and as a result of spontaneous racemization of proteins with a long in vivo lifetime. See Helfman and Bada, PNAS, 72:2891-2894 (1975). Racemization is a naturally occurring process that over time, will convert naturally occurring L-amino acids into a racemic mixture of both L- and D- amino acids. A limited portion of the structure of several approved peptide-like pharmaceuticals include a few D-amino acids.
  • Such products include the widely known antibiotics Valinomycin, Gramicidin A, Gramicidin S, and also the vasopressin analog Desompressin (RPR), Lupron (Abbott), Synarel (Syntex), Sandostatin (Sandoz), SK&- 110679 (Smithkline Beecham), and Decapeptyl (Ipsen- Beuafor/Akzo).
  • RPR vasopressin analog Desompressin
  • Lupron Abbott
  • Synarel Synarel
  • Sandostatin Sandostatin
  • SK&- 110679 Smithkline Beecham
  • Decapeptyl Ipsen- Beuafor/Akzo
  • D-peptides are made by chemical synthesis, using techniques that are well-known in the art.
  • D-peptides can be synthesized using stepwise addition of D-amino acids in a solid-phase synthesis method involving the use of appropriate protective groups.
  • Solid phase peptide synthesis techniques commonly used for L-peptides are described by Meinhofer, Hormonal Proteins and Peptides, vol. 2, (New York 1983); Kent, et al. , Ann. Rev. Biochem. , 57:957 (1988); and Bodanszky et al. , Peptide Synthesis, (2d ed. 1976), all of these references are incorporated by reference herein.
  • D-amino acids for use in the solid-phase synthesis of D-peptides can be obtained from a number of commercial sources.
  • D-peptides and peptides that contain mixed L- and D-amino acids are known in the art.
  • peptides containing exclusively D-amino acids have been synthesized. See Zawadzke et al. , J. Am. Chem. Soc., 114:4002-4003 (1992); Milton et al., Science 256: 1445-1448 (1992).
  • Ligand analogs that are known in the art are small organic molecules, L-peptides, and modified L-peptides.
  • D-antibodies that specifically bind receptors or ligands or substrates have not been described in the literature and there remains a need for such D-antibodies and D-peptides that are analogs of ligands and receptors as well as methods for their identification and production.
  • analogs of biologically active peptide and protein including but not limited to hormones and neuropeptides, wherein the analogs are comprised exclusively or essentially of D-amino acids and are biologically functional.
  • One aspect of the present invention concerns generating D-peptides and D-proteins composed entirely of D-amino acids which will interact with a natural or artificial L-peptide or L-protein target, such as a biological receptor in the body.
  • Novel compositions of matter comprising antibody-like entities comprised of D-amino acids (D-antibodies or D-peptides that are analogs of ligands or receptors) and engineered derivative forms, and a process for producing those novel antibody-like entities in such a way as to achieve required biological and pharmaceutical functions, are provided.
  • the general method allows production of a molecular recognition surface (such as Van der Waal's and electrostatic surface) of a D-peptide (i.e.
  • D-peptides a polypeptide or protein composed entirely or largely of D- amino acids, including D-antibodies or fragments thereof) in such a way that it will mimic the molecular recognition surface of a natural biological ligand composed of L-amino acids, while retaining the advantageous properties of D- peptides.
  • D-peptides will be advantageously resistant to proteolysis in the gut, resistant to serum and tissue proteases, and are relatively immunoiogically inert.
  • the D-antibodies of the invention or fragments thereof, including their antigen binding loops, or redesigned components thereof, will have increased resistance to proteolysis in the gut and throughout the body. Compositions comprising the D-antibodies and other D-polypeptides of the invention are contemplated.
  • D-peptide analogs of L-antibodies which preserve the binding specificity of the antigen binding loops are possible, such that relatively small structures which are no-longer antibody-like in character essentially function as analogues of natural biological ligands.
  • Alternative screening methods to refine the immunological approach including the phage-generation of FAb fragments that is known in the art and is an alternative to the standard monoclonal antibody method of generating an antibody to a specific antigen.
  • an additional advantage over the use of normal L-antibodies is that the antibody may be drastically modified including for example retaining only the FAb fragment in a D- analog or retaining the basic antigen recognition and binding loops placed on a scaffold (here, of D-amino acids) in the same orientation as in the original antibody.
  • the design need not directly modify the antibody recognition region, but the resulting D-antibodies or D-polypeptides may differ considerably in form from antibodies.
  • D-polypeptides are usually both resistant to proteolysis and much less immunogenic than the corresponding L- polypeptides.
  • monoclonal antibodies are raised against the
  • a binding site on a protein ligand would be an example of typical interest as a structure comprising the aforesaid epitope, domain, or protein.
  • the sequence of the monoclonal antibodies raised against the epitope domain or protein are then determined, and the whole antibody or any part thereof which includes the antigen binding site or part thereof is synthesized as the D-amino acid sequence corresponding to the sequence or part of sequence in the monoclonal antibody.
  • the resulting antibodies or subfragments thereof which are composed entirely of D-amino acids generally interact with the original natural, biological L- forms of the above mentioned epitopes, domains or whole proteins.
  • D-polypeptides of the invention Unlike humanized antibodies, heavy modification of the D-polypeptides of the invention, including reduced size of the peptide chain is possible without typically requiring design to maintain humanization, and the resulting D-polypeptide may be longer lasting in vivo than pharmacologically functional analogs of proteins, such as hormones and neuropeptides and natural antibodies.
  • the invention comprises the method described above, wherein the synthesis of a D-peptide corresponding to the monoclonal antibody comprises determination of the binding site of the monoclonal antibody and the L- amino acid sequence of said binding site and synthesis of a D-peptide that corresponds to the L-amino acid sequence or sequences of the binding sites of the monoclonal antibody, i.e. the D-peptide has the same amino acid sequence as the L-amino acid sequence of the binding site, except that the D-peptide has D-amino acids in place of the L-amino acids of the monoclonal antibody binding sites.
  • the invention provides synthesized D-antibodies comprising polypeptides or peptides comprised of a D-amino acid sequence that corresponds to an L-amino acid sequence of an L-antibody consisting of L-amino acids.
  • the D-antibodies of the invention are comprised exclusively or essentially of D-amino acids or the corresponding enantiomers of amino acid analogs.
  • the D-antibodies of the invention may contain one or more of the achiral glycine amino acid residues.
  • the D-antibodies of the invention can include a receptor, a substrate binding site on an enzyme, an epitope of a receptor that interferes with ligand binding when an antibody is bound to the receptor, a ligand binding site of a receptor, a co-factor binding site on an enzyme and a sugar binding site on a protein.
  • the D-peptides can include a ligand for a receptor, a substrate for an enzyme binding site, a peptide hormone for a receptor, a non-peptide hormone for a receptor, a neurotransmitter for a receptor, a co- factor for a co-factor binding site on an enzyme and a sugar for a sugar binding site on a protein.
  • L-antibodies that are generated in response to D- peptide antigens can be produced using the known methods of monoclonal antibody production and phage-generation of FAb fragments.
  • the method of generating a D-peptide that binds to a ligand or receptor entails creating a D-version of the ligand or receptor, probing or screening a library made of L-peptides with the D-version of the ligand or receptor, detecting "hits" or L-peptides that bind to the D-version of the ligand or receptor and then synthesizing a D-version of the L-peptides.
  • the D-version of the L-peptide is capable of binding to the L-version of the ligand or receptor.
  • Such D-versions of the L-peptide are often referred to herein as D-peptides or D- antibodies.
  • the first step is to choose a protein target (or non-peptide ligand), such as a receptor, or enzyme to which one wishes to design a novel D-peptide ligand.
  • a protein target such as a receptor, or enzyme to which one wishes to design a novel D-peptide ligand.
  • a ligand D-peptide will provide either inhibition of the normal function as an antagonist, or in some cases of the normal function activation as an agonist.
  • the target proteins or protein components (such as a ligand binding site) are synthesized in their mirror image form, by making them of D-amino acids (D-polypeptides).
  • the resulting molecules may be referred to D- polypeptides, such as D-receptors, D-enzymes, or D-hormones, parts of which correspond in sequence to normal L-receptors, L-enzymes and L-hormones, respectively.
  • D-receptor will be used to refer to all protein targets whether D-receptors, D-enzymes, D-hormone or any other D-protein, or to parts of such proteins, for which an agonist, antagonist, or any other novel ligand is desired.
  • a ligand binding domain of a D-receptor would be made by first looking at the amino acid sequence of the ligand binding domain of the natural receptor, and then one may re-synthesize the same sequence using D-amino acids instead of L-amino acids.
  • Ligand binding sites with molecular recognition surfaces contacting at least two surfaces of the ligand are preferred, especially when the recognition surfaces are less than 100 amino acids apart in the amino acid sequence of the protein.
  • the second step is to perform combinatorial screening of an L-peptide library by probing with the D-receptor or D-polypeptide.
  • Combinatorial screemng permits the creation of a diverse set of peptides that can be then converted into D-peptides.
  • immunological production of antibodies or recombinant production of antibodies can be used to create a diverse set of L-peptides that can be converted into the corresponding D-peptides.
  • Synthetic peptide libraries can be prepared combinatorially in advance, and then screened against the D-receptor.
  • synthetic peptide libraries provide greater chemical diversity when non-naturally occurring amino acids are used, especially amino acids with the same charge as naturally occurring amino acids but differing in the distance that the charge is located from the peptide backbone. Alterations in distance can be accomplished with 1 , 2, or 3 atom extenders of the negative or positive charge, preferably carbon atoms are used.
  • Recombinant peptide libraries can be used as well, as known in the art.
  • phage display D-peptide approach One type of preferred combinatorial library is the phage display D-peptide approach. Typically, one would first prepare a bacteriophage display with normal L-peptides using methods known in the art. Alternatively, other recombinant libraries could be used that rely on plasmids to produce L-peptides. Here the combinatorial presentation of many different peptides or proteins is implemented indirectly, by random mutation or partly random mutation or combinatorial selection of nucleotide segments of the DNA expressing the proteins. Preferably in recombinant libraries, such as phage display libraries, a short section of DNA encodes a mutated region that will become part or all of the L-peptide. Preferably, the mutated region is not randomly mutated and does not contain all possible amino acid sequences for a 3 to 10 or a 5 to 8 amino acid mutated region.
  • mutations are selective and usually introduce at predetermined amino acid positions, conservative mutations, such as swapping polar amino acids for different polar amino acids, negatively charged amino acids for different negatively charged amino acids and hydrophobic amino acids for different hydrophobic amino acids.
  • conservative mutations such as swapping polar amino acids for different polar amino acids, negatively charged amino acids for different negatively charged amino acids and hydrophobic amino acids for different hydrophobic amino acids.
  • Such mutated regions be used with synthetic peptide libraries and can are preferably used with D-antibody phage display.
  • Bacteriophage libraries are inexpensive and easy to manipulate, Bacteriophage display or "phage display” is widely used. It was originally developed as "fusion phage" technology (S.F. Parmley and G.P. Smith, Gene, 73:305-318, 1988, herein inco ⁇ orated by reference) to describe the chimeric nature of coat proteins displaying random amino acids at their N-termini.
  • the earliest phage display libraries developed as a technology for more general screening purposes, appeared in a number of laboratories in 1990 and were typically implemented by cloning a synthetic piece of DNA into gene III of an fd or M13 filamentous bacteriophage (J.K. Scott and G.P. Smith, Science 249:386-
  • a further advantage of this combinatorial screening is to increasingly refine the screening with further cycles of screening.
  • additional cycles of screening offer higher stringency conditions to select for tighter binding, i.e. a lower apparent Kd.
  • Higher stringency conditions can be accomplished by increasing the temperature, lowering or increasing the ionic strength, increasing the concentration of chaotropic agents and the like, or a combination thereof.
  • the method allows access to at least IO 8 different peptides in a tube of approximately 1 ml volume.
  • the L-peptides are detected and then sequenced or identified as to which sequence they represent using a detection or identification means, many of which are known in the art for combinatorial libraries.
  • the binding or enriched peptides respectively may be subjected to amino acid sequencing e.g. by Edman degradation, or identified by other means.
  • hits may identified by position on a grid on which the combinations were generated in a controlled manner, or by chemically labeled tags including radio-labeled tags, by unique linked nucleic acid labels, by their final mass as determined by mass spectrometry (see PCT/US95/03355, which is herein incorporated by reference), by iterative resynthesis and screening of smaller subpools or submixtures (see Zuckermann et al. , J. of Medicinal Chem., 37(17): 2678-2685 (1994)(incorporated by reference herein), or by any combination of these or other known techniques.
  • the sequences are usually deduced by amplification and inspection of the DNA sequence coding for the peptide of interest.
  • L-peptide or L-protein sequences are noted and the D-peptides or D-proteins are then made with the same amino acid sequence, using D-amino acids rather than L-amino acids.
  • D-peptides or D-proteins correspond to the mirror images of the selected combinatorial peptides.
  • Such molecules can now interact with the original L-target receptor having the amino acid sequence corresponding to the D-receptor that was made for the screen.
  • receptors again include for present purposes receptors proper, enzymes, hormones and other proteins against which one may wish to make a D-peptide ligand.
  • An important aspect of the invention is the display of L-antibodies or parts thereof such as Fab fragments by cloning into the phage, not only to refine the binding site (recognition loops) to the target, but to refine the frame, particularly the Fab fragment bearing the antigen binding site.
  • all the peptides and protein displayed on the phage will contain at least the antigenic binding loops of the monoclonal antibodies raised against the original D-antigen, and which will carry the recognition in D-form to interact with the original L-form of the antigen, say a natural receptor in the body.
  • the invention includes that these loops may be modified by phage display for refinement purposes, and this also includes that a degree of design may be carried out so that refinements of the antigenic binding site sequences are raised in the phage.
  • the modification envisaged by phage display include extensive modification of the frame, replacement by non-antibody frames (folds of other proteins) to carry the recognition loops, and a high degree of reduction in size including removal of the frame possibly including insertion of Cystine cross links.
  • Modification of antibody components and selection by phage display is known in the state of the art but without regard to D-antibodies, and is known as use of "semisynthetic antibody libraries ".(C. Barbas et al., Proc. Nat. Acad. Sci. USA, 89,4457,1992).
  • the antigen recognition loops themselves, being three on the heavy chain and three on the light chain, may be presented and refined for binding, to be synthesized as D-peptides without a supporting molecular scaffold, individually or joined, for example with oligoglycine spacers. Alternatively they may be presented on a scaffold other than an Fab fragment or other antibody component, in which the active loops are replaced by three selected antibody recognition loops. Typically these will be the loops identified in binding studies as binding most strongly to the target or its analog, but are expected to be the three loops of the heavy chain as in most antibodies where studies have been carried out, these have more extensive interaction with the antigen. Similarly, the two larger loops of the heavy chain may be selected on occasion without the third smaller loop. In seeking a protein scaffold, engineering may be required including using one or more loops in the retro (backwards) sequence direction. In all the above examples, the initial proposed structures are typically to be refined by phage display.
  • these reagents may need refinement as a drug, by rational design by exploring a structure-activity relationship of analogues, or by modeling studies at the receptor where this is of known structure, and may optionally include for design and refinement purposes comparison with retroinverso forms of known natural or discovered or designed L-peptide ligands and also optionally by comparison with the receptor sequence. Further refinement may be required for enhanced oral delivery and availability and improved pharmacokinetic properties. Further chemical modification including added groups including for example extension at either terminus with additional amino acid residues may be required. One may also require a presentation medium such as a liposome system to be used. Peptide extensions for targeting and cell entry can include for example L-amino acid based antibodies and L-hormones preferably of long half life.
  • Peptide and protein extensions and additions which may be made of D-amino acids and still be active in D-forms include magainins, cecropins and other lytic peptides, viral cell entry peptides, endosome escape peptides of viral origin, peptides of for example lgG3 or milk protein origin which may cross the blood brain barrier.
  • antibodies composed exclusively or essentially of D- amino acids interact with peptides and proteins made of L-amino acids in effectively e same way as the corresponding L-antibodies made of L-amino acids will interact with peptides or proteins made of D-amino acids.
  • the pharmacological target can be any natural endogenous or other biological or non-natural ligand or receptor, including a hormone, neuropeptide, virus particle, other biologically active peptide, or enzyme.
  • L-polypeptide or L- protein sequences of the target may represent an epitope or set of epitopes in or near the binding site of a receptor or other protein target, or the subdomain or domain of the receptor or other target, or the whole or part of the receptor or other target.
  • the L-polypeptide or L-protein amino acid sequences are used to generate the corresponding D-amino acid sequence, which is the same sequence as that of the L-polypeptide or L-protein sequence of the target amino acids differing only in enantiomeric form and comprising D-amino acids.
  • the present invention provides a method for identifying a D-antibody or a D-peptide that is an analog of a ligand or a receptor comprising: selecting the ligand or a receptor; determining the L-amino acid sequence comprising either the ligand or the ligand binding site of the receptor; synthesizing a D-peptide corresponding to the L-peptide or L-polypeptide comprising the ligand or the ligand binding site of the receptor; preparing a monoclonal antibody to said D- peptide; synthesizing a D-antibody comprising a D-amino acid sequence corresponding to an L-amino acid sequence of the monoclonal antibody; and assaying said D-antibody for specific binding to the ligand or the ligand binding site of the receptor.
  • the D-peptide or D-polypeptide corresponding to the L- peptide or L-polypeptide has the same amino acid sequence from the carboxy terminus to the amino terminus as the L-peptide or L-polypeptide, except that the L-amino acids are replaced with their corresponding D-stereoisomers.
  • the ligands can be non-peptides, non-naturally occurring ligands, and peptides comprising a mixture of D- and L-amino acids.
  • any epitope of a ligand or receptor might be synthesized using D-amino acids and attached to a carrier molecule to render it immunogenic. In such a case, the D- epitope may be regarded as a hapten.
  • a D-protein in excess of approximately 35 residues may not always be immunogenic without such a carrier molecule, since it is unlikely to be cleaved an presented on major histompatibility antigen to the T- cell receptor.
  • D-epitopes may for example include activation of a receptor by inducing dimerization of receptor proteins or oligomerization generally.
  • the method is modified such that the enantiomer of the non- peptide ligand or receptor is synthesized and used to generate an antibody that specifically binds to it. Then, the L-amino acid sequence of the antibody or a portion thereof, such as its Fab fragment, is determined, and from the L-amino acid sequence the corresponding D-antibody is synthesized.
  • the method can also be applied to achiral ligands or receptors or molecules.
  • the method comprises using the achiral ligand, receptor or other molecule to generate an L-antibody; determining the amino acid sequence of the L-antibody or a portion thereof, such as the Fab fragment; synthesizing the corresponding D-antibody; and assaying the D-antibody for specific binding to the achiral ligand, receptor or other molecule.
  • the selection of the chiral or achiral, natural or non-naturally occurring, ligand or receptor or other molecule to which a D-antibody is desired for binding is accomplished using information about such molecules in the literature as well as any information regarding the amino acid sequence, if any, of such molecules.
  • the selection of a ligand binding site of an L-polypeptide or naturally occurring protein is accomplished by reference to the literature regarding amino acid sequences of known ligand binding sites, receptors or ligands. If any such molecules are peptides that have not yet been sequenced, one of ordinary skill can sequence the peptides using well-known peptide sequencing methods.
  • D-polypeptide antigen that corresponds to an L-amino acid sequence of a peptide ligand, receptor or other molecule, is accomplished using chemical synthesis.
  • the D-polypeptide antigen is synthesized, preferably using known solid phase stepwise Merrifield-type peptide synthesis techniques developed for L-peptide synthesis, but in this case using D-amino acids or protected D-amino acids in the stepwise synthesis.
  • Other methods of synthesizing D-polypeptide antigens are contemplated, including covalent bonding of monomers that were produced via stepwise synthesis.
  • the means of synthesizing the D- polypeptide antigens and other D-polypeptides or D-antibodies of the invention are known in the art, and the invention can be practiced using methods of D- polypeptide synthesis that are yet to be developed.
  • the solid-phase synthesis of D-peptides comprises: attaching a protected D-amino acid to an inert solid support through the unprotected carboxyl or amino group of the D-amino acid; selectively removing the protecting group on the amino or carboxyl group of the first D-amino acid; introducing the next D- amino acid having the appropriate amino or carboxyl group protected and reacting it under conditions that permit formation of an amid linkage between the second D-amino acid and the first D-amino acid already attached to the solid support. The protecting group on the amino or carboxyl group of the second D-amino acid is then selectively removed. This procedure is repeated for each successive addition of a D-amino acid to the synthesized D-peptide.
  • the chemically synthesized D-peptides can be chemically ligated using methods known in the art.
  • the D-polypeptide antigen is synthesized, it is used to produce antibodies.
  • the antibodies to be produced can be either monoclonal antibodies or phage-generated FAb fragments, both methods are known in the art.
  • a carrier molecule may be required to render the D-peptide or protein immunogenic, particularly since it may not be able to cleave the D-molecule for presentation as major histocompatibility complex antigens to the T-cell.
  • Such molecules are available commercially as kits already primed with chemical groups to join to the peptide epitope. Proteins typically available include Keyhole Limpet Hemocyanin and Bovine Serum Albumin.
  • the monoclonal antibodies or phage- generated FAb fragments are screened using methods known in the art for specific binding to the D-polypeptide antigen.
  • the selected antibody or a portion of the antibody, such as the modified Fab fragment or a single-chain Fv or disulfide- bonded Fv fragment is then isolated and sequenced.
  • Fv fragments are the smallest functional moieties of antibodies required for binding of an antigen. Reiter et al., Protein Engineering, 7(5):697-704 (199 ).
  • the L-amino acid sequence of the antibody or portion representing a binding site, Fab fragment, single-chain Fv fragment or disulfide-bonded Fv fragment is then used to determine the corresponding D-amino acid sequence of a D-antibody of the invention.
  • the D- antibody of the invention which includes D-amino acid sequences corresponding to an entire L-antibody or portions thereof, including the Fab fragment, the single- chain Fv fragment and the disulfide-bonded Fv fragments, is synthesized as described above.
  • phage display of antibody it is known that antibodies are or parts of antibodies displayed can be refined by phage display in their binding recognition loops and in part of the supporting antibody fold; such antibodies are termed "semisynthetic" (CF. Barbas et al. , Proc. Nat. Acad. Sci. USA 89-4457, 1992).
  • CF. Barbas et al. Proc. Nat. Acad. Sci. USA 89-4457, 1992.
  • Normally modification to the frame of the antibody or Fab fragment confers no advantage in clinical use since humanization will most typically be lost.
  • the principle significance of the invention is that the protease-resistant properties and reduced immunogenicity of D-antibodies implies a degree of built-in humanization, such that modification to the frame is not in general a restriction.
  • the invention allows for all such modifications to the frame such as would normally risk loss of humanization, including reduction of size of the frame as discussed above, in the practice of phage display, and including progressive reduction of the size of the antibody frame in phage display.
  • This includes reduction in steps with enrichment by passing the cloned Fab head with randomized amino acids by phage display on progressively smaller frames, such that screening is performed at each size reduction step to retain activity.
  • too large a size reduction in a single step would risk total loss of activity due to too large a change of interactions between loop and frame.
  • This invention greatly broadens the scope of application of D-proteins by readily allowing production of biologically functional forms.
  • the invention also provides a means for more direct conversion of information in the human genome into pharmaceutical products.
  • the D-antibodies of the invention which include both D-analogs of complete antibodies as well as D-analogs of portions of antibodies, can be used in therapeutic compositions, as agonists or antagonists or catalysts.
  • the D- antibodies can be used to specifically bind target cells that express specific antigens, such as viral or bacterial antigens.
  • the D-antibodies which are not only D-antibodies but also D-peptide analogs of Fab fragments or other portions of L-antibodies, have several advantages over the corresponding L-antibodies.
  • the D-antibodies of the invention are essentially D-peptides that are analogs of ligands or receptors that are capable of binding to peptide or non- peptide, natural or non-naturally occurring, chiral or achiral molecules.
  • the D-antibodies can be designed to bind to either receptors or ligands or any chiral or achiral, natural or non-naturally occurring molecules.
  • a D- antibody capable of specifically binding to a ligand is desired, then it is produced according to the methods described herein, using the ligand as either the template from which an amino acid sequence is obtained (if the ligand is a polypeptide) or as the antigen against which L-antibodies, whether monoclonal or phage-generated, are raised.
  • Ligands include naturally occurring polypeptides or peptides, non- peptides such as hormones, non-naturally occurring peptides or non-peptides, and chiral or achiral compounds.
  • a D-antibody that specifically binds a receptor is desired, it is produced according to methods described herein.
  • the receptor or a portion thereof is used as the original polypeptide from which an L-amino acid sequence can be determined and the corresponding D-polypeptide antigen synthesized.
  • Use of combinatorial libraries are well known in the art. See PCT/IB95/00560 (Hodges et al., filed June 13, 1995) and PCT/US95/03355 (Benkovic et al., filed March 23, 1995) both of which are inco ⁇ orated by reference herein.
  • Ligand generally refers to a member of a ligand binding pair, i.e. a ligand and a receptor.
  • a portion of the ligand or surface of the ligand specifically binds a portion of a receptor or a surface of a receptor.
  • a ligand can exert a biological effect, i.e. a biological ligand.
  • the ligand 's overall structure or molecular weight is smaller than the receptor, but this is not a necessary condition.
  • a ligand is often a L-peptide or L-polypeptide, but other non-peptide molecules, including steroids, co-factors, neurotransmitters, neurotransmitter analogs, non-peptide hormones, non-peptide hormone analogs, and nucleotides, nucleosides and sugars and modified forms of non-peptide molecules are contemplated as ligands.
  • Non-naturally occurring and achiral ligands are also contemplated.
  • ligands will not include D-polypeptides or D-amino acids.
  • the affinity of the ligand for the receptor is less than ImM, preferably 1 pM to 100 ⁇ M or less than 100 ⁇ M, more preferably 10 pM to 1 ⁇ M or less than 1 ⁇ M, and most preferably 100 pM to 100 nM or less than 100 nM.
  • a D-ligand refers to a ligand with a D- configuration, usually a non-peptide.
  • Receptor generally refers to a member of a ligand binding pair.
  • a receptor need not be considered a biological receptor with a specific biological function. Instead, receptor refers to a member of the ligand binding pair with a molecular recognition surface that binds, usually non-covalently, to the ligand.
  • the receptor will have at least one ligand binding site with such a surface.
  • the ligand binding site will be solvent accessible, preferably water accessible.
  • the ligand binding site will often be composed of L-amino acids linked together by peptide bonds, such as a biological receptor for a peptide hormone.
  • the receptors might be an organic molecule, such as crown ether, or a nucleic acid, such as DNA.
  • D-antibody refers to an antibody or fragment thereof that includes a D- amino acid sequence, including modifications to maintain the fragment or separate fragments in the conformation that they would have in the entire D-antibody (and hence also the mirror image to the conformation that the corresponding L-peptide segments would have in the monoclonal L- Antibody).
  • the fragments will typically be the binding recognition loops of the antibodies that are involved in direct interaction with antigen, there being three such loops on the heavy chain and tliree such loops on the light chain of the antibody.
  • Fab antibody fragment Fab fragment fragment.
  • Modifications can be of various types. Generally, a D-antibody amino acid sequence will be entirely made of D-amino acids. In some instances it will be preferable to include L-amino acids in the amino acid sequence of a D-antibody.
  • D-antibodies can include single chain FAbs, or any subfragments or analogues thereof, where the heavy and light chains are joined end-to-end via a flexible linker, and mini-bodies, where the heavy and light chains are joined, preferably by a disulfide or similar bond by the introduction of two residues like cysteines, one in each chain. See Reiter et al., supra.
  • the ligand binding site will be made of at least 90% D-amino acids, more preferable at least 95 % , and most preferably 96% to
  • a D-amino acid sequence is normally used for making the protein (or peptide) ligand or receptor in the process of making a D-antibody that resembles the receptor or the ligand.
  • the D- antibody is made using the D-amino acid sequence of the protein ligand.
  • the D-antibody is made using the D-amino acid sequence of the protein receptor.
  • Such D-amino acid ligands and receptors can be considered a D-polypeptide antigen.
  • D-amino acid sequence of either the protein receptor or ligand is composed entirely of D-amino acids, but substitution of L-amino acids is tolerated in regions of the protein that do not adversely alter the Kd by more than two orders of magnitude and more preferably one order of magnitude compared to an all D-amino acid protein ligand or receptor.
  • D-antigen refers to antigen with a D- configuration.
  • L-antibody refers to antibody made from L-amino acids, including those found in nature, made by immunizing mammals, made by phage and other methods known in the art for making truncated or modified antibodies, minibodies, including, but not limited to single chain antibodies or immunoreactive fragments thereof.
  • the invention also provides for detection methods.
  • the antibodies and peptides of the invention provide for peptidase resistant molecules, such compounds of the invention are particularly suited for detection of analytes.
  • the method of detecting an analyte comprises contacting the analyte with a D-antibody, and detecting a complex of the analyte and D-antibody.
  • Many variations in the method of detection can be accomplished with the antibodies of the invention.
  • the antibodies of the invention can be used for instance in ELISA assays and separation methods can be applied comprising an additional step of separating the complex from unbound D-antibody. Washing steps are not required if complementation assays, as known in the art, are used that change the rate of production of a detectable signal.
  • Such assays can be conducted using a kit containing the necessary assay components.
  • analytes can be detected using the antibodies of the invention and affinity selection for purification of the desired analyte(s).
  • analytes will be those for which an antibody can be generated by methods known in the art at the time of the filing of this application and those methods later discovered.
  • the analyte is a ligand for a receptor, a substrate for a binding site on an enzyme, a peptide hormone, a non-peptide hormone, a neurotransmitter, a co ⁇ factor, or a sugar.
  • the antibodies of the invention can be labelled if so desired by covalent or non-covalent means to facilitate detection.
  • labels include enzymes capable of generating a detectable signal, fluorescent compounds (including FITC), radioactive atoms (including C14 and 1125), biotin, and avidin.
  • labels are attached at a region of the antibody that does not include the ligand binding site or at the C- or N- terminus. Labels can also include toxins to kill cells or inhibit cell proliferation.
  • the antibodies of the invention can also be used as biosensors in either using enzymatic or electrical detection methods or a combination of the two.
  • Ligand specific electrodes can be generated using the antibodies of the invention as taught in the art for other biological molecules that bind ligands, particularly antibodies.
  • the invention also includes pharmaceutical compositions and methods of modulating biological conditions.
  • antibodies of the invention can be used to inhibit ligand binding to a receptor by contacting an effective amount of D-antibody to a receptor, thus blocking the ligand from binding to the receptor.
  • the amount will vary from 1 ⁇ g to lOOmg, more preferably from 10 ⁇ g to lOmg or more than .01 mg, and most preferably from .1 mg to 10 mg.
  • compositions comprise a physiologically suitable carrier and the compounds of the invention.
  • Such carriers include buffers and coatings as known in the art.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur des procédés de production et d'utilisation d'anticorps D et de peptides D. Lesdits anticorps et peptides sont des analogues de ligands ou de récepteurs pouvant se fixer spécifiquement aux peptides L, aux peptides contenant à la fois des L-aminoacides et des D-aminoacides de peptides chiraux et non chiraux non naturels, et à des composés chiraux et non chiraux non peptidiques. Lesdits peptides et anticorps résistent à la protéolyse dans l'intestin et dans le corps et sont moins immunogènes que leurs contreparties, les anticorps L et les peptides L. L'invention porte également sur leur procédé de fabrication.
PCT/US1996/016358 1995-10-10 1996-10-10 Production de peptides d : methodes et compositions WO1997013522A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP9515247A JP2000500431A (ja) 1995-10-10 1996-10-10 Ｄ−ペプチドの発生：方法および組成物
AU74422/96A AU7442296A (en) 1995-10-10 1996-10-10 Generating d-peptides: methods and compositions
EP96936413A EP0862447A1 (fr) 1995-10-10 1996-10-10 Production de peptides d : methodes et compositions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US550895P 1995-10-10 1995-10-10
US60/005,508 1995-10-10
US1443396P 1996-03-28 1996-03-28
US60/014,433 1996-03-28

Publications (1)

Publication Number Publication Date
WO1997013522A1 true WO1997013522A1 (fr) 1997-04-17

Family

ID=26674440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/016358 WO1997013522A1 (fr) 1995-10-10 1996-10-10 Production de peptides d : methodes et compositions

Country Status (5)

Country Link
EP (1) EP0862447A1 (fr)
JP (1) JP2000500431A (fr)
AU (1) AU7442296A (fr)
CA (1) CA2234723A1 (fr)
WO (1) WO1997013522A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001520397A (ja) * 1997-10-20 2001-10-30 ディバーシス リミテッド 種々のリガンドによるファージ提示ライブラリーのスクリーニング方法
EP1194157A1 (fr) * 1999-04-21 2002-04-10 Hisamitsu Pharmaceutical Co., Inc. Polypeptide de forme d induisant une immunotolerance et techniques d'utilisation
US7655602B2 (en) 2002-07-03 2010-02-02 Bio Science International, Inc. Peptides comprising aromatic D-amino acids and methods of use
US20140296479A1 (en) * 2011-04-08 2014-10-02 Gwangju Institute Of Science And Technology D-aptide and retro-inverso aptide with maintained target affinity and improved stability
US9238676B2 (en) 2012-05-17 2016-01-19 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079152A (en) * 1987-05-28 1992-01-07 Scripps Clinic And Research Foundation Antibody combining sites that exhibit stereoselective synthase activity, and methods using the same
US5248611A (en) * 1987-05-28 1993-09-28 Scripps Clinic And Research Foundation Stereoisomer separation method using antibody combing site-containing molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079152A (en) * 1987-05-28 1992-01-07 Scripps Clinic And Research Foundation Antibody combining sites that exhibit stereoselective synthase activity, and methods using the same
US5248611A (en) * 1987-05-28 1993-09-28 Scripps Clinic And Research Foundation Stereoisomer separation method using antibody combing site-containing molecules

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1992, Vol. 114, ZAWADZKE et al., "A Racemic Protein", pages 4002-4003. *
PROC. NATL. ACAD. SCI., Vol. 91, October 1994, GUICHARD et al., "Antigenic Mimicry of Natural L-peptides With Retro-Inversopeptidomimetics", pages 9765-9769. *
SCIENCE, Vol. 256, 05 June 1992, MILTON et al., "Total Chemical Synthesis of a D-Enzyme: The Enantiomers of HIV-1 Protease Show Demonstration of Reciprocal Chiral Substrate Specificity", pages 1445-1448. *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001520397A (ja) * 1997-10-20 2001-10-30 ディバーシス リミテッド 種々のリガンドによるファージ提示ライブラリーのスクリーニング方法
EP1194157A1 (fr) * 1999-04-21 2002-04-10 Hisamitsu Pharmaceutical Co., Inc. Polypeptide de forme d induisant une immunotolerance et techniques d'utilisation
EP1194157A4 (fr) * 1999-04-21 2002-08-14 Hisamitsu Pharmaceutical Co Polypeptide de forme d induisant une immunotolerance et techniques d'utilisation
US7655602B2 (en) 2002-07-03 2010-02-02 Bio Science International, Inc. Peptides comprising aromatic D-amino acids and methods of use
US20140296479A1 (en) * 2011-04-08 2014-10-02 Gwangju Institute Of Science And Technology D-aptide and retro-inverso aptide with maintained target affinity and improved stability
US9238676B2 (en) 2012-05-17 2016-01-19 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
US9644004B2 (en) 2012-05-17 2017-05-09 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
US9999650B2 (en) 2012-05-17 2018-06-19 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
US10272132B2 (en) 2012-05-17 2019-04-30 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors

Also Published As

Publication number Publication date
EP0862447A1 (fr) 1998-09-09
JP2000500431A (ja) 2000-01-18
AU7442296A (en) 1997-04-30
CA2234723A1 (fr) 1997-04-17

Similar Documents

Publication Publication Date Title
US5723584A (en) Biotinylation of proteins
Fang et al. Review on biomimetic affinity chromatography with short peptide ligands and its application to protein purification
CA2697108C (fr) Recepteurs peptidiques cyclises double mutants inhibiteurs d'anticorps anti-recepteurs .beta.1-adrenergiques
US5780221A (en) Identification of enantiomeric ligands
JP2003525487A (ja) 抗体模倣物および他の結合タンパク質のタンパク質骨格
Lane et al. Epitope mapping using bacteriophage peptide libraries
RU2008104610A (ru) Новые методики фагового дисплея
WO1996023813A1 (fr) Peptides et composes se fixant aux domaines sh2
AU773957B2 (en) Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction
EP0825997A1 (fr) Identification de ligands enantiomeres
WO1997013522A1 (fr) Production de peptides d : methodes et compositions
EP2391637A1 (fr) Nouveaux homologues peptidiques pour l'inhibition d'anticorps dirigés contre l'adrénorécepteur bêta1
JPH0570484A (ja) ペプチドおよびその塩
Barredo et al. Peptide Affinity Chromatography Applied to Therapeutic Antibodies Purification
Nakaie et al. Use of commercial anion-exchange resins as solid support for peptide synthesis and affinity chromatography
JP2002053596A (ja) アポトーシス誘導ペプチド、そのスクリーニング方法およびアポトーシス誘導剤
JP2019535704A (ja) 結合性ペプチド
JP2002293794A (ja) インスリンに対して結合性を有するペプチド
JPH05262788A (ja) ペプチド類、その設計方法及び製造方法並びに受容体上の生理活性ペプチドの結合部位の決定方法
JPH0570481A (ja) ペプチドおよびその塩
Liu Development of cyclic peptidyl ligands through a combinatorial library approach
JPH0578391A (ja) ペプチドおよびその塩
Ma Molecular scaffolds: Design, synthesis and biological activities of linear and cyclic peptides with multiple pharmacophores
JP2002187899A (ja) ルシフェラーゼに対して結合性を有するペプチド
Bordas Solid phase amino acid protection, peptide construction and synthetic peptide use in defining protein stabilities, functions and in identifying contributing residues of enzymatic active sites

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2234723

Country of ref document: CA

Ref country code: CA

Ref document number: 2234723

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 515247

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996936413

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996936413

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996936413

Country of ref document: EP